Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is commonly diagnosed in obese subjects; however, it is not rare among lean individuals. Given the absence of traditional risk factors, it tends to remain under-recognised. The metabolic profiles of lean NAFLD patients are frequently comparable to those of obese NAFLD patients. Though results from several studies have been mixed, it has been generally revealed that lean subjects with NAFLD have minor insulin resistance compared to that in obese NAFLD. Several genetic variants are associated with NAFLD without insulin resistance. Some data suggest that the prevalence of steatohepatitis and advanced fibrosis do not differ significantly between lean and obese NAFLD; however, the former tend to have less severe disease at presentation. The underlying pathophysiology of lean NAFLD may be quite different. Genetic predispositions, fructose- and cholesterol-rich diet, visceral adiposity and dyslipidaemia have potential roles in the pathogenic underpinnings. Lean NAFLD may pose a risk for metabolic disturbances, cardiovascular morbidity or overall mortality. Secondary causes of hepatic steatosis are also needed to be ruled out in lean subjects with NAFLD. The effectiveness of various treatment modalities, such as exercise and pharmacotherapy, on lean NAFLD is not known. Weight loss is expected to help lean NAFLD patients who have visceral obesity. Further investigation is needed for many aspects of lean NAFLD, including mechanistic pathogenesis, risk assessment, natural history and therapeutic approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 4×
“There are several well-known animal models and genetic diseases that can lead to hepatic steatosis without significant adiposity or IR.”
BackgroundInfluentialNonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Park, Y.-W., Zhu, S., Palaniappan, L., Heshka, S., Carnethon, M. R., & Heymsfield, S. B. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.4.427 · Cited by 2,074 · cited 2×
“These normal BMI subjects develop hepatic steatosis after becoming a little heavier during adult life, with a 2 to 10 kg increase in weight, which was almost entirely due to an increase in body fat.(23,24) WC and neck circumference are commonly used as surrogate markers of visceral adiposity.”
BackgroundFatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.
Wanless, I. R., & Lentz, J. S. (1990) · Hepatology · doi:10.1002/hep.1840120505 · Cited by 1,191
Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity
Fabbrini, E., Magkos, F., Mohammed, B. S., Pietka, T., Abumrad, N. A., Patterson, B. W., Okunade, A., & Klein, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904944106 · Cited by 972 · cited 1×
“Several new studies suggest an important role of intrahepatic fat in the development of dyslipidaemia and IR in humans.(64,65) In cases with IR, hepatic fat deposition is further propagated, as the resulting hyperinsulinemia and hyperglycaemia activate SREBP and carbohydrate-SREBP, respectively.”
BackgroundThe metabolically obese, normal-weight individual revisited.
Ruderman, N., Chisholm, D., Pi-Sunyer, X., & Schneider, S. (1998) · Diabetes · doi:10.2337/diabetes.47.5.699 · Cited by 893
Association between body-mass index and risk of death in more than 1 million Asians
Zheng, W., McLerran, D. F., Rolland, B., Zhang, X., Inoue, M., Matsuo, K., He, J., Gupta, P. C., Ramadas, K., Tsugane, S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010679 · Cited by 885 · cited 7×
“Overall, the risk of death among Asians, as compared with Europeans, seems to be more strongly affected by a low BMI than by a high BMI.(81) Dela Cruz et al.”
BackgroundInfluentialBugianesi, E., Gastaldelli, A., Vanni, E., Gambino, R., Cassader, M., Baldi, S., Ponti, V., Pagano, G., Ferrannini, E., & Rizzetto, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1682-x · Cited by 770
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease
Petersen, K. F., Dufour, S., Hariri, A., Nelson-Williams, C., Foo, J. N., Zhang, X.-M., Dziura, J., Lifton, R. P., & Shulman, G. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907295 · Cited by 428
Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men
Petersen, K. F., Dufour, S., Feng, J., Befroy, D., Dziura, J., Man, C. D., Cobelli, C., & Shulman, G. I. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608537103 · Cited by 403 · cited 3×
“NAFLD has been shown to be associated with IR independently of BMI,55 and studies have reported that IR is present in a significant proportion of lean NAFLD patients even without other metabolic risk factors.7,56 A study revealed that lean, non-alcoholic Asian Indians had 2- to 3-fold increase in IR in comparison to m…”
ResultInfluentialSpeliotes, E. K., Butler, J. L., Palmer, C. D., Voight, B. F., & Hirschhorn, J. N. (2010) · Hepatology · doi:10.1002/hep.23768 · Cited by 362 · cited 5×
“Various genetic factors are known to confer susceptibility to NAFLD in individuals without IR.(46,47,57) Patients with mutations in adipose triglyceride lipase and comparative gene identification-58 have been found to have severe steatosis but no IR.”
BackgroundInfluentialHepatic lipid metabolism and non-alcoholic fatty liver disease
Tessari, P., Coracina, A., Cosma, A., & Tiengo, A. (2009) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.12.015 · Cited by 314 · cited 1×
“These transcription factors up-regulate de novo lipogenesis and, subsequently, hepatic lipid accumulation.(66) Furthermore, cholesterol metabolites such as oxysterols mediate SREBP1c activation, ultimately enhancing lipogenesis and hepatic steatosis.”
Gastaldelli, A., Harrison, S. A., Belfort-Aguilar, R., Hardies, L. J., Balas, B., Schenker, S., & Cusi, K. (2009) · Hepatology · doi:10.1002/hep.23116 · Cited by 285 · cited 1×
“A study has reported that patients with NASH have severe adipose tissue IR independent of the degree of obesity.(60) In a recent study, Feldman et al.”
Background
Cited by
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
“alcoholic fatty liver disease, congenital and acquired lipodystrophy (HIV treatment), genetic factors (polymorphisms in PNPLA3), congenital defects of metabolism (lysosomal acid lipase deficiency), endocrine disorders (polycystic ovarian syndrome, hypothyroidism, growth hormone deficiency), drug use (amiodarone, metho…”
BackgroundLi, J., Zou, B., Yeo, Y. H., Feng, Y., Xie, X., Lee, D. H., Fujii, H., Wu, Y., Kam, L. Y., Ji, F., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30039-1 · Cited by 1,031
Mediterranean diet and nonalcoholic fatty liver disease
Anania, C., Perla, F. M., Olivero, F., Pacifico, L., & Chiesa, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i19.2083 · Cited by 353
(2021) · doi:10.1007/s12072-021-10242-2 · Cited by 64
Metadata
- Authors
- Kumar, R., & Mohan, S.
- Venue
- Journal of Clinical and Translational Hepatology
- Publisher
- Xia & He Publishing
- Published
- 2017-07-05
- Volume
- XX
- Issue
- XX
- Pages
- 1-8
- ISSN
- 2225-0719 (ISSN-L)
- 2310-8819
- OpenAlex
- W2729639506
- Cited by
- 102
- References
- 14
- FWCI
- 10.57
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.